RASP — Actavia Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $6.02m
- $6.23m
Annual cashflow statement for Actavia Life Sciences, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.936 | -5.35 | -0.876 | -0.687 | -4.44 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.396 | 5.05 | 0.706 | 0.303 | 4.06 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.452 | 0.048 | -0.124 | 0.071 | 0.371 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.093 | -0.251 | -0.293 | -0.313 | -0.009 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | 0 | — | — | — | — |
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.1 | 0.215 | 0.29 | 0.341 | 0.044 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.007 | -0.036 | -0.003 | 0.029 | 0.036 |